8-K: BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO Following Resignation

BioSig Technologies has appointed Ferdinand Groenewald as interim CFO and principal accounting officer, effective June 5, 2024, following the resignation of Frederick D. Hrkac.

Summary

• BioSig Technologies announced the resignation of Frederick D. Hrkac as acting chief financial officer and principal accounting officer, effective June 5, 2024.
• Ferdinand Groenewald has been appointed as interim chief financial officer, principal accounting officer, and vice president of finance, also effective June 5, 2024.
• Mr. Groenewald's appointment is under a consulting agreement with a fixed monthly compensation of $15,000, plus reimbursement for business expenses.
• The consulting agreement can be terminated by either party with 30 days' notice.
• Mr. Groenewald has extensive experience, including previous roles as CFO and chief accounting officer at Muscle Maker, Inc., and current role as vice president of finance at Alaunos Therapeutics, Inc.
• The company issued a press release on June 10, 2024, announcing Mr. Groenewald's appointment.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is a change in key personnel, the company has quickly filled the role with an experienced individual. However, the resignation of the previous CFO introduces some uncertainty.

Positives

• The company has quickly filled the CFO and principal accounting officer roles with an experienced professional.
• Ferdinand Groenewald brings a strong background in finance and accounting, including experience as a CFO and chief accounting officer at other public companies.
• The consulting agreement provides a clear compensation structure and termination process.

Negatives

• The resignation of the previous CFO and principal accounting officer may indicate some internal challenges.
• The appointment of an interim CFO suggests the company may be in a period of transition.

Risks

• The company is undergoing a change in key financial leadership, which could create uncertainty.
• The company's ability to execute its financial strategy may be impacted by the transition.
• The company's forward-looking statements are subject to various risks and uncertainties, including the ability to maintain Nasdaq listing and achieve cost reduction targets.

Future Outlook

The company's future performance is subject to various risks and uncertainties, including the ability to maintain Nasdaq listing, achieve cost reduction targets, and successfully commercialize its products.

Management Comments

• BioSig's CEO, Anthony Amato, stated that Mr. Groenewald's financial expertise will be a key asset to help drive strategic decisions.
• Mr. Amato also noted that Mr. Groenewald's understanding of financial principles will align with the company's broader business strategy and play a pivotal role in shaping growth opportunities to increase shareholder value.

Industry Context

The appointment of a new CFO is a common event for publicly traded companies, especially those undergoing strategic changes or facing financial challenges. The medical technology sector is competitive, and strong financial leadership is crucial for success.

Comparison to Industry Standards

• The appointment of an interim CFO is not uncommon in the industry, especially during periods of transition.
• The compensation package for the interim CFO appears to be within the typical range for similar roles in comparable companies.
• Ferdinand Groenewald's experience as a CFO and director in other Nasdaq-listed companies is a positive sign, as it demonstrates his familiarity with the regulatory and financial reporting requirements of public companies.
• Alaunos Therapeutics, Inc., where Mr. Groenewald currently serves as VP of Finance, is a comparable company in the biotech sector, suggesting that his experience is relevant to BioSig's business.

Management Changes

Stakeholder Impact

• Shareholders may experience some uncertainty due to the change in financial leadership.
• Employees may be affected by the transition, but the appointment of an experienced interim CFO should provide stability.
• Customers and suppliers are unlikely to be directly impacted by this change.

Next Steps

• The company will continue to execute its business strategy with the new interim CFO.
• The company may begin a search for a permanent CFO.

Key Dates

Keywords

CFO, Chief Financial Officer, Interim CFO, Principal Accounting Officer, Financial Reporting, Executive Change, BioSig Technologies, BSGM, Ferdinand Groenewald, Frederick D. Hrkac